AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) announced on October 29, 2026 that its wholly owned subsidiary, NeuralCloud Solutions Inc., has entered into an agreement with Etisense SAS, a Lyon, France-based preclinical life sciences technology company, to integrate NeuralCloud's MaxYield™ ECG signal-processing engine into Etisense's LASA telemetry software. The collaboration targets animal-model ECG labeling and analysis for pharmacology, safety-toxicology, and disease-model research. The agreement marks an expansion of NeuralCloud's footprint into the European preclinical research market and broadens the use cases for MaxYield™ beyond clinical settings.

Key Points

  • AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) via subsidiary NeuralCloud Solutions Inc.
  • NeuralCloud signed an agreement dated October 27, 2026 with Etisense SAS to integrate MaxYield™ into the LASA preclinical telemetry software platform
  • Collaboration begins with large-animal models (canine, porcine, primate), with potential extension to small-animal models following validation; the initial validation stage is provided at no charge to Etisense
  • Investors may be watching whether Etisense approves progression beyond the validation stage and whether the integration advances to online licensing for ongoing customer use

MaxYield™ Integration into Etisense's LASA Platform

Under the agreement, NeuralCloud will provide MaxYield™ as an AI-powered ECG labeling and analysis layer embedded beneath Etisense's existing LASA software workflow. MaxYield™ is designed to improve ECG signal clarity, isolate and label waveform components, calculate ECG intervals, detect fiducial points, and generate structured outputs for downstream analysis. Etisense will retain its customer relationships, platform workflow, and final review process. The agreement is non-exclusive, and NeuralCloud retains all intellectual property rights in MaxYield™.

Phased Validation Approach Across Animal Models

The collaboration is structured in stages. NeuralCloud will first complete a validation stage at no charge to Etisense using representative ECG files. Progression beyond this validation phase is subject to Etisense's written approval. The companies intend to begin with large-animal models, including canine, porcine, and primate models, which are commonly used in pharmacology and safety-toxicology studies. Extension into small-animal models, such as mouse and rat models, is intended following successful validation of large-animal performance, which the release states could broaden MaxYield™'s application across additional research areas.

Strategic Significance for NeuralCloud in Preclinical and European Markets

The announcement describes the agreement as a further step in NeuralCloud's expansion into the preclinical animal research market, adding a partnership opportunity in Europe. Etisense's DECRO® wearable telemetry solution captures ECG, respiratory function, and locomotor activity data without implant surgery, aligning with 3Rs animal welfare principles. The release states that combining Etisense's ecosystem with MaxYield™'s capabilities aims to provide more efficient ECG interpretation workflows for researchers, laboratories, contract research organisations, and pharmaceutical partners. The immediate share price impact was not clear from available public information.

Regulatory Status and Scope of the Agreement

The release explicitly states that MaxYield™ has not received FDA or Health Canada clearance, authorisation, or approval for clinical or diagnostic use. The Etisense collaboration is limited to animal-model ECG labeling and preclinical research workflows. The release notes that any future regulated clinical or diagnostic use of MaxYield™ or related NeuralCloud products would be subject to applicable regulatory requirements, validation, and approvals.